<DOC>
	<DOCNO>NCT00905489</DOCNO>
	<brief_summary>The primary objective establish pharmacokinetic ( PK ) profile steady state nevirapine XR HIV infect child &gt; =3 &lt; 18 year age . This phase I trial open-label , multiple dose , non-randomized cross-over study . Patients complete last visit PK trial ( visit 7 ) enter Optional Extension Phase ( OEP ) Investigational New Drug ( IND ) withdrawn ; nevirapine XR become approve available prescription give country ; , patient enrolls compassionate use program . During OEP , nevirapine XR safety efficacy information collect .</brief_summary>
	<brief_title>A Phase I Multiple Dose Pharmacokinetic Study Nevirapine Extended Release ( XR ) HIV-1 Infected Children .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed date write informed consent parent legal guardian prior admission . Active assent must give patient child and/or adolescent capable understanding provide study information . 2 . HIV1 infect male female &gt; = 3 &lt; 18 year old . 3 . BSA &gt; = 0.58 m2 patient use BSA calculate nevirapine IR dose ; BW &gt; = 12.5 kg patient use BW calculate nevirapine IR dose screen visit . 4 . Treated nevirapine IR base regimen least 18 week prior screen visit ( Visit 1 ) ; modification ARV background therapy within last 2 week prior screen . 5 . An HIV VL &lt; 50 copies/mL receive nevirapine IR last measure VL document medical record obtain within period 5 month prior screen visit . 6 . An HIV VL &lt; 50 copies/mL screen visit . 7 . A stable decreasing CD4+ cell count accord investigator 's opinion . 8 . Acceptable screen laboratory value indicate adequate baseline organ function accord opinion investigator . 9 . ALT AST &lt; = 2.5 X ULN ( DAIDS Grade 1 ) . 10 . Serum creatinine level &lt; = 1.3 X ULN ( DAIDS Grade 1 ) . 11 . Patients able swallow tablet . Exclusion criterion : 1 . Any AIDSrelated AIDS defining illness unresolved stable treatment least 8 week prior screen visit . 2 . Diseases HIV infection condition , investigator 's opinion , would interfere study . 3 . Patients diagnose malignant disease receive systemic chemotherapy anticipate receive therapy participation trial . 4 . Use investigational medication vaccine within 28 day prior Visit 1 trial . 5 . Use immunomodulatory drug within 28 day Visit 1 trial ( e.g. , interferon , cyclosporin , hydroxyurea , interleukin 2 ) . 6 . Concomitant protease inhibitor ( PI ) treatment . 7 . Unwillingness abstain ingest substance study may alter plasma drug concentration interaction cytochrome P450 system ( Appendix 10.2 ) . 8 . Female patient childbearing potential : positive serum pregnancy test screening , breast feeding , plan become pregnant , willing use doublebarrier method</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>